Upcoming ODAC meetings
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review Pfizer's Fragmin (dalteparin sodium) Sept. 6 for extended treatment of symptomatic venous thromboembolism, proximal deep vein thrombosis and/or pulmonary embolism to reduce the recurrence of VTE in cancer patients. The panel will also discuss Genta's chronic lymphocytic leukemia treatment Genasense, the firm announced July 27 (1"The Pink Sheet" July 31, 2006, In Brief). Genta had initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory panel review. On Sept. 7, ODAC will discuss trial design issues for Abraxis Bioscience's Abraxane for treatment of node-positive breast cancer. Abraxane originally cleared FDA January 2005 for metastatic breast cancer. The two-day meeting will be held at the Silver Spring, Md. Hilton from 8 a.m. to 5 p.m. [Editor's note: To 2watch a webcastor order a video/DVD of advisory committee meetings, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
Genasense AC review
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 6, the company said. The oblimersen injection plus chemotherapy regimen is currently pending at FDA under a standard review, with an Oct. 29 user fee date. Genta initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory committee review (1"The Pink Sheet" May 24, 2004, p. 12)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.